Inventor · disambiguated record
Blaise S. Lippa
Also filed as: LIPPA BLAISE · LIPPA BLAISE S · LIPPA BLAISE SCOTT
24 granted patents·11 pending applications·191 citations·filing 2000–2024
95Inventor score
Files withMORPHIC THERAPEUTIC INC19PFIZER4UNIV LELAND STANFORD JUNIOR3CUBIST PHARM INC2BIOSOURCE PHARM INC1
Top patents by PatentIndex Score
35 records- 0196US12145935B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2023·Granted Nov 19, 2024·4 cites·20 claims
- 0296US11795167B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Oct 24, 2023·5 cites·19 claims
- 0395US11827621B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Nov 28, 2023·5 cites·9 claims
- 0495US11021480B2Inhibiting (α-V)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2020·Granted Jun 1, 2021·8 cites·2 claims
- 0594US12415796B2Inhibitors of (αv)(β6) integrinMORPHIC THERAPEUTIC INC·Filed 2023·Granted Sep 16, 2025·2 cites·8 claims
- 0694US11739087B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Aug 29, 2023·5 cites·9 claims
- 0794US11046669B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2019·Granted Jun 29, 2021·8 cites·35 claims
- 0894US6624189B2Byrostatin analogues, synthetic methods and usesUNIV LELAND STANFORD JUNIOR·Filed 2000·Granted Sep 23, 2003·48 cites·30 claims
- 0993US11046685B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2018·Granted Jun 29, 2021·8 cites·42 claims
- 1093US11040955B2Inhibitors of (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2018·Granted Jun 22, 2021·8 cites·59 claims
- 1193US10759756B2Antagonists of human integrin α4β7MORPHIC THERAPEUTIC INC·Filed 2019·Granted Sep 1, 2020·7 cites·42 claims
- 1292US7256286B2Bryostatin analogues, synthetic methods and usesUNIV LELAND STANFORD JUNIOR·Filed 2003·Granted Aug 14, 2007·29 cites·19 claims
- 1390US8415307B1Antibiotic compositions for the treatment of gram negative infectionsCURRAN WILLIAM V·Filed 2011·Granted Apr 9, 2013·21 cites·13 claims
- 1489US11370773B1Inhibiting human integrin (alpha-4) (beta-7)MORPHIC THERAPEUTIC INC·Filed 2021·Granted Jun 28, 2022·2 cites·24 claims
- 1587US7585869B2Substituted heterocylces for the treatment of abnormal cell growthPFIZER·Filed 2004·Granted Sep 8, 2009·22 cites·15 claims
- 1685US12459942B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2024·Granted Nov 4, 2025·0 cites·18 claims
- 1785US12221416B2Antagonists of human integrin α4β7MORPHIC THERAPEUTIC INC·Filed 2023·Granted Feb 11, 2025·0 cites·20 claims
- 1884US2025223289A1Inhibitors of (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 1983US11174228B2Antagonists of human integrin (α4)(β7)MORPHIC THERAPEUTIC INC·Filed 2020·Granted Nov 16, 2021·1 cites·20 claims
- 2081US11104661B1Inhibiting human integrin (α-4) (β-7)MORPHIC THERAPEUTIC INC·Filed 2020·Granted Aug 31, 2021·1 cites·24 claims
- 2180US9193729B2Inhibiting transient receptor potential ion channel TRPA1CUBIST PHARM INC·Filed 2013·Granted Nov 24, 2015·6 cites·11 claims
- 2272US2022340529A1Antagonists of human integrin (alpha4)(beta7)MORPHIC THERAPEUTIC INC·Filed 2021·Application pending·0 cites
- 2369US10428072B2Inhibiting the transient receptor potential A1 ion channelLILLY CO ELI·Filed 2018·Granted Oct 1, 2019·1 cites·58 claims
- 2468US2020071322A1Inhibiting (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2019·Application pending·0 cites
- 2567US2020354359A1Inhibiting (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2020·Application pending·0 cites
- 2661US8906866B2Antibiotic compositions for the treatment of gram negative infectionsBIOSOURCE PHARM INC·Filed 2013·Granted Dec 9, 2014·0 cites·9 claims
- 2755US9394308B2Inhibiting the transient receptor potential A1 ion channelMERCK SHARP & DOHME·Filed 2014·Granted Jul 19, 2016·0 cites·8 claims
- 2854US2007270485A1Byrostatin analogues, synthetic methods and usesUNIV LELAND STANFORD JUNIOR·Filed 2007·Application pending·0 cites
- 2951US2023219949A1Inhibitors of (alpha-v)(beta-6) integrinHARRISON BRYCE A·Filed 2022·Application pending·0 cites
- 3050US2014158116A1Inhibiting trpa1 for the treatment of asthmaCUBIST PHARM INC·Filed 2013·Application pending·0 cites
- 3147US2008051419A1Amine derivatives useful as anticancer agentsPFIZER·Filed 2007·Application pending·0 cites
- 3243US2009111805A1Bicyclic heteroaromatic derivatives useful as anticancer agentsPFIZER·Filed 2006·Application pending·0 cites
- 3338US7276602B2Isothiazole derivatives useful as anticancer agentsPFIZER·Filed 2003·Granted Oct 2, 2007·0 cites·18 claims
- 3436US2017050966A1Inhibiting the transient receptor potential a1 ion channelHYDRA BIOSCIENCES INC·Filed 2015·Application pending·0 cites
- 3531US2017216295A1Ccr9 antagonist compoundsPANDYA BHUAMIK·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →